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Prostate cancer (PCa) is the second most common cause of cancer-specific deaths in the U.S. Unfortunately, the 
underlying molecular mechanisms for its development and progression remain unclear. Studies have established 
that microRNAs (miRNAs) are dysregulated in PCa. The intron-derived microRNA-1207-3p (miR-1207-3p) is 
encoded at the non-protein coding gene locus PVT1 on the 8q24 human chromosomal region, an established PCa 
susceptibility locus. However, miR-1207-3p in PCa had not previously been investigated. Therefore, we explored 
if miR-1207-3p plays any regulatory role in PCa. We discovered that miR-1207-3p is significantly 
underexpressed in PCa cell lines in comparison to normal prostate epithelial cells, and that increased expression 
of microRNA-1207-3p in PCa cells significantly inhibits proliferation, migration, and induces apoptosis via 
direct molecular targeting of fibronectin type III domain containing 1 (FNDC1). Our studies also revealed 
significant overexpression of FNDC1, fibronectin (FN1) and the androgen receptor (AR) in human PCa cell lines 
as well as tissues, and FNDC1, FN1, and AR positively correlate with aggressive PCa. These findings, recently 
published in Experimental Cell Research, are the first to describe a novel miR-1207-3p/FNDC1/FN1/AR novel 
regulatory pathway in PCa. 
Keywords: miR-1207-3p; prostate cancer; FNDC1; FN1; AR 
To cite this article: Dibash K. Das, et al. A novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate 
cancer. RNA Dis 2018; 5: e1503. doi: 10.14800/rd.1503. 
Copyright: © 2018 The Authors. Licensed under a Creative Commons Attribution 4.0 International License which 
allows users including authors of articles to copy and redistribute the material in any medium or format, in addition 
to remix, transform, and build upon the material for any purpose, even commercially, as long as the author and original 
source are properly cited or credited. 
Prostate cancer (PCa) is the most commonly diagnosed 
male cancer in the western world [1, 2]. With an estimated 
22,800 newly diagnosed men in the US in 2015, PCa is a 
major cause of cancer morbidity and mortality [3]. Although 
there has been progress made in the field, several areas of 
critical unmet needs remain in PCa, such as the molecular 
mechanisms underlying its development and progression [1, 2, 
4-6]. The complexity of the disease lies in its heterogeneity [1,
2, 7]. The current tool for screening for PCa, prostate specific
antigen (PSA), is highly controversial as it is not 
PCa-specific and has a high false positive rate [8, 9]. This poor 
correlation leads to adverse consequences associated with 
unnecessary diagnosis and overtreatment of non-aggressive 
PCa [8-10]. Currently, there are no biomarkers available that 
are effective for the early detection of PCa and sensitive 
enough to discriminate between indolent and aggressive PCa 
[1, 11, 12]. Therefore, the search continues for improved and 
reliable biomarkers which offer specificity, and improve risk 
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stratification and clinical outcomes for patients. 
Progressively increasing data have established an 
important role for microRNAs (miRNAs) in human cancers 
[13-16]. miRNAs are small single-stranded non-coding RNAs, 
which play a vital role in post-transcriptional gene regulation 
[16]. With their locations typically in regions of the genome 
that are overexpressed, deleted or epigenetically modified, 
their regulatory effects are extensive [17]. Understanding their 
roles in the pathogenesis of cancer such as their differential 
expression in the different stages of cancer may inform their 
potential use as prognostic biomarkers or as possible 
therapeutic targets. Studies have implicated various roles of 
miRNAs in PCa [13, 18-20]. However, much work is still 
required to elucidate which specific miRNAs directly 
promote or suppress PCa and what their mechanisms of 
regulation and action are.  
It is now well known that the 8q24 human chromosomal 
locus has profound genomic instability in PCa [2, 21-24]. 
Several studies, including one published recently from our 
lab, “PVT1 exon 9: a potential biomarker of aggressive 
prostate cancer?” Int. J. Environ. Res. Public Health 2016, 
13(1)12, have shown that the PVT1 gene locus, located on 
the 8q24 chromosomal locus, is dysregulated in PCa [21]. 
PVT1 has at least 12 different exons and encodes six 
microRNAs, including microRNA-1207-3p (miR-1207-3p) 
[1, 5, 21, 24]. However, to the best of our knowledge, no study 
had been previously performed to determine the role and 
biological functions for miR-1207-3p in PCa. Our study, 
recently published in Experimental Cell Research Volume 
348, Issue 2, Pages 190–200, is the first to determine the role 
of miR-1207-3p in PCa.  
To investigate the expression profile, the functional role, 
and the molecular mechanisms of action of miR-1207-3p in 
PCa, a panel of 8 prostate cell lines modeling different 
clinical characteristics of PCa was used because of the 
widely known heterogeneity of PCa [1]. The panel of cell 
lines included the RWPE-1 (non-tumorigenic prostate 
epithelial cell line, Caucasian male (CM)), WPE1-NA22 
(derived from RWPE-1, indolent, androgen-dependent, CM), 
MDA PCa 2b (aggressive, androgen dependent, from a male 
of African ancestry (moAA)), PC-3 (aggressive, 
androgen-independent, CM), E006AA (indolent, 
androgen-independent, moAA), E006AA-hT (derived from 
E006AA, aggressive, androgen-independent, moAA), 
LNCaP (aggressive, androgen-dependent, CM) and C4-2b 
(derived from LNCaP, aggressive, androgen-independent, 
CM)[1]. In this study, we discovered that miR-1207-3p was 
significantly underexpressed in all the human PCa cell lines 
in comparison to RWPE-1, by real-time quantitative 
polymerase chain reaction analysis [1]. We observed 
approximately a 50% decrease in miR-1207-3p expression in 
androgen-dependent PCa cell lines, and a further reduction, 
nearly 80%, in androgen-independent cell lines [1]. The data 
suggest that miR-1207-3p underexpression may be 
associated with the onset and progression of PCa and could 
be used as a new predictive biomarker for development of 
androgen-independent PCa. 
To explore the molecular mechanisms through which 
miR-1207-3p exerts its PCa- inhibitory effects, the molecular 
targets of miR-1207-3p have to be identified. No previous 
studies had ever shed light on the direct molecular targets of 
miR-1207-3p in any system. Using two miRNA molecular 
target prediction algorithms, we identified fibronectin type 
III domain containing 1 (FNDC1) as a putative molecular 
target of miR-1207-3p. FNDCI contains the conserved 
‘fibronectin type III domain’ of fibronectin (FN1) [1, 25, 26]. 
FN1 is a known regulator of tumorigenesis with roles in 
cellular proliferation, migration and apoptosis [1, 27-31]. Many 
Figure 1. A novel miR-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer. MicroRNA-1207-3p inhibits 
proliferation and migration and induces apoptosis of prostate cancer cells by the direct molecular targeting of the 3’UTR of 
FNDC1. miR-1207-3p induced loss of FNDC1expression leads to the sequential loss of FN1 and AR expression. 
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of the FN1 domains (type I, type II and type III) have been 
found in many other molecules due to exon shuffling [1, 25, 26]. 
The biological function of FNDC1 has not been well studied. 
The FNDC1 gene is located on the 6q25.3 human 
chromosomal region [26]. The limited data available on 
FNDC1 show that FNDC1 was formally known as Activator 
of G protein signaling 8 (AGS8) and it has been previously 
observed to be expressed in different tissue types including 
fetal cartilage, thyroid gland, heart, kidney and adipose tissue 
[26, 32-34]. In addition, FNDC1 may have a role in 
inflammation and hypoxia-induced apoptosis of 
cardiomyocytes [32, 33]. However, there had been no reported 
functional role for FNDC1 in PCa. We investigated the 
association between miR-1207-3p and its potential target, 
FNDC1. We observed that FNDC1 protein expression was 
consistently higher in all the PCa cell lines compared to 
RWPE1, and overexpression of miR-1207-3p significantly 
inhibits FNDC1 protein expression [1]. In addition, 
dual-luciferase reporter assay and subsequent RNA pulldown 
assay confirmed, for the first time, that FNDC1 is a direct 
molecular target of miR-1207-3p [1]. Furthermore, our 
custom-designed FNDC1 siRNA confirmed that the effects 
of loss of FNDC1 expression positively correlates to the 
effects of overexpression of miR-1207-3p on PCa cellular 
functions [1]. Consequently, our study is the first to 
demonstrate that FNDC1 is directly targeted by miR-1207-3p 
and associated with PCa. 
To determine if a relationship exists between 
miR-1207-3p and FN1, we also analyzed mRNA and protein 
expression of FN1. Our data revealed that compared to the 
non-tumorigenic RWPE-1 cell line, FN1 mRNA and protein 
expression was significantly higher in all the PCa cell lines[1]. 
Moreover, overexpression of miR-1207-3p downregulates 
FN1. As expected, knockdown of FN1 by our 
custom-designed FN1 siRNA demonstrated similar effects on 
PCa cellular functions to that observed by the overexpression 
of miR-1207-3p [1]. These findings demonstrate that FN1 is a 
component of the molecular pathway regulated by 
miR-1207-3p in PCa. 
It is well established that aberrant AR expression and 
activity play a critical role in the development and 
progression of PCa [6, 35-37]. And given our observation that 
miR-1207-3p expression was less in androgen-independent 
PCa cell lines than androgen –dependent PCa cell lines, we 
wanted to investigate if miR-1207-3p regulates AR in PCa. 
Inverse trends between AR protein expression and 
miR-1207-3p were observed. AR protein expression, similar 
to FN1 and FNDC1 protein expression, is overexpressed in 
PCa cell lines [1]. In addition, we demonstrated that the 
molecular effects of miR-1207-3p: loss of FNDC1 
expression and consequent loss of FN1 expression leads to 
loss of AR expression [1]. Therefore, we demonstrated that 
miR-1207-3p regulates AR expression via FNDC1 and FN1. 
Thus, our work published in Experimental Cell Research 
Volume 348, Issue 2, Pages 190–200, is the first description 
of the miR-1207-3p/FNDC1/FN1/AR regulatory pathway in 
PCa [1].  
To investigate the role of miR-1207-3p in proliferation, 
migration and apoptosis of PCa cells, dose response 
experiments were initially performed which determined that 
a 50nM concentration of a miR-1207-3p inhibitor and a 
miR-1207-3p mimic showed maximal specific effect on 
miR-1207-3p expression. And this concentration was used to 
make the novel discovery that increased expression of 
microRNA-1207-3p in PCa cells significantly inhibits 
migration, and proliferation, and induces apoptosis via direct 
molecular targeting of FNDC1 [1]. These functional 
experiments clearly demonstrate a mechanism by which 
miR-1207-3p regulates key cellular processes dysregulated in 
the development and progression of PCa. 
Our novel pathway has important clinical implications as 
miRNAs possess several key features that make them 
attractive prostate cancer biomarkers [13, 14, 38]. Therefore, we 
investigated the clinical relevance of miR-1207-3p in human 
PCa patients. Two independent publicly available gene 
expression data sets that had been deposited in the Oncomine 
database were analyzed [39, 40]. Our analysis of the Oncomine 
database demonstrated convincing novel evidence of 
concurrent overexpression of FNDC1, FN1, and AR in the 
most clinically significant PCa, metastatic PCa, in 
comparison to primary tumors in both data sets [1]. In another 
independent study that our team conducted at the Moffitt 
Cancer Center, we discovered that FN1 overexpression in 
prostate tumors positively correlated with overall death and 
PCa-specific death [1]. To our knowledge this is the first 
description of FN1 as a prognostic biomarker in human 
clinical PCa. Thus, we can conclude that miR-1207-3p 
correlates with tumor aggressiveness. Further, we 
independently investigated prostate cancer RNA-seq datasets 
deposited at the Array Express archive of the European 
Bioinformatics Institute (EBI). The RNA-seq dataset was 
analyzed in the RNA-sequencing pipeline implemented on 
the bioinformatics web platform, Galaxy. The data revealed 
that a subset of prostate cancers demonstrated concurrent 
increased FN1 and AR expression in PCa samples as 
compared to normal prostate samples [1]. Based on these 
findings, we strongly believe our miRNA-1207-3p is a 
promising candidate biomarker for aggressive prostate cancer 
and further research is being pursued. 
In summary, as shown in Figure 1, the findings of our 
work collectively describe a miR-1207-3p/FNDC1/FN1/AR 
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novel regulatory pathway in PCa, for the first time. Overall, 
we identified that miR-1207-3p is significantly 
underexpressed in PCa cells, and demonstrated that 
miR-1207-3p is a vital regulator of cellular proliferation, 
migration and apoptosis of PCa cells [1]. Notably, convincing 
clinical data was discovered indicating that this novel 
molecular pathway may be an important predictor of cancer 
recurrence and metastasis in PCa [1]. Consequently, 
miR-1207-3p may have potential diagnostic, prognostic, and 
therapeutic applications in PCa. 
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